You just read:

Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich's Ataxia

News provided by

Chondrial Therapeutics, Inc.

Aug 03, 2017, 09:00 ET